Achillion Pharmaceuticals Inc (ACHN.O) Company Profile | Reuters.com
Edition:
United States

Profile: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

7.76USD
10:29am EDT
Change (% chg)

$-0.02 (-0.26%)
Prev Close
$7.78
Open
$7.91
Day's High
$7.91
Day's Low
$7.65
Volume
260,379
Avg. Vol
1,523,331
52-wk High
$10.95
52-wk Low
$5.57

Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.

The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir. ACH-4471 is a potent and specific inhibitor of factor D, which has demonstrated complete suppression of the complement alternative pathway with a single oral dose in non-human primates. In preclinical studies, the compound has demonstrated dose-dependent inhibition of hemolysis and deposit of C3, a complement protein, on blood cells, which can lead to further hemolysis. The Company has synthesized over 1,200 factor D inhibitor compounds from which it plans to select one or more development candidates to advance into the clinic. The Company has completed approximately three Phase IIa clinical trials with odalasvir, including the -007 trial with sovaprevir, the -005 study, which examined the use of odalasvir with ribavirin alone, and the Proxy Doublet study, which examined the use of odalasvir in combination with sofosbuvir, a nucleotide nonstructural protein 5B (NS5B) polymerase inhibitor marketed by Gilead Sciences, Inc., under the brand name Sovaldi. The Company has completed a Phase II clinical trial that evaluated approximately 12 weeks of treatment consisting of sovaprevir and its NS5A inhibitor, odalasvir, with ribavirin for the treatment of genotype 1 HCV (the -007 trial).

The Company has developed tools that enable to manage its compounds and advance its programs. Achillion Automated Chemistry Platform (AACP) is a software that facilitates synthesis of thousands of small molecules in parallel by automating several cumbersome steps involved. Compound Acquisition and Repository Tracking (CART) streamlines scientists' ability to select and acquire compounds for lead identification and optimization. CHEM-ACH is a data mining software that allows analysis of its compounds and their biological activities. Competitive Intelligence & Data Mining (CIDM) is a Web application that analyzes publicly available information to display competitive information, including clinical and preclinical development activities, intellectual property and scientific literature. ComplementWiki is an in-house database of ongoing and completed complement related drug development and clinical trial designs and results. HCVWiki is an in-house database of ongoing and completed hepatitis C virus (HCV) therapy clinical trial designs and results. Preclinical Study Tracking System (PSTS) is a Web interface, which is used for accessing the details of its preclinical studies.

The Company competes with Alexion, Akari, Alnylam, Amyndas, Apellis, Bio Cryst, Omeros, Ra Pharma, True North, Genentech, Novartis, Abbvie Pharmaceuticals, Enanta, Gilead Sciences, Merck and Regulus Therapeutics.

Company Address

Achillion Pharmaceuticals Inc

300 George St
NEW HAVEN   CT   06511-6624
P: +1203.6247000
F: +1203.6247003

Company Web Links